Humacyte, Inc. (HUMA)
(Real Time Quote from BATS)
$5.79 USD
-0.07 (-1.11%)
Updated Jul 10, 2024 12:25 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Humacyte, Inc. (HUMA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.25 | $15.00 | $6.00 | 40.78% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Humacyte, Inc. comes to $8.25. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 40.78% from the last closing price of $5.86.
Analyst Price Targets (6 )
Broker Rating
Humacyte, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
7/2/2024 | The Benchmark Company | Bruce D Jackson | Strong Buy | Strong Buy |
4/1/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
3/8/2024 | Piper Sandler | Allison M Bratzel | Not Available | Hold |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $8.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | -0.23 |